The improved treatment of cognitive disorders in schizophrenia has become a priority for the National Institute of Mental Health, because of the evidence that cognitive dysfunction is the chief cause of chronic disability from the illness. Currently available antipsychotic drugs do not effectively address this dysfunction. One promising lead comes from studies of nicotinic acetylcholine receptors. For the alpha7-receptor there is genetic and neurobiological evidence of involvement in schizophrenia. Nicotine has some neurocognitive effects, but they are not clinically significant and there is considerable health risk associated with nicotine in any form. alpha7-agonists have the promise of safer, more targeted effects and may not have nicotine's considerable tachyphylaxis. In the previous funding period, we completed a Phase 1 study of 3-2,4 dimethoxybenzylidene anabaseine (DMXB-A), a partial agonist at alpha7-nicotinic receptors, in schizophrenia. A positive neurocognitive effect was found. The proposed continuation of this project will test the drug's effectiveness using the newly available MATRICS Battery, developed by NIMH to assess neurocognitive effects of new drugs potentially useful in schizophrenia. We will also determine the time course of drug effect, with the intent of developing administration paradigms that prolong drug action throughout the day. We will also determine if the drug interacts with nicotine for schizophrenics who smoke. In a final experiment, we will determine if clinically useful of DMXB-A are sustained during periods of administration of one moYrth or longer. Persons with schizophrenia have difficulty with many aspects of their thinking, including their attention and their ability to learn. The drugs that they currently take are not entirely helpful, and many of them turn to smoking. We are studying a new, nicotine-like drug, that does not have the harmful effects of tobacco, but may help persons with schizophrenia to think better. ? ? ?

Agency
National Institute of Health (NIH)
Institute
National Institute of Mental Health (NIMH)
Type
Research Project (R01)
Project #
2R01MH061412-05A1
Application #
7148598
Study Section
Neural Basis of Psychopathology, Addictions and Sleep Disorders Study Section (NPAS)
Program Officer
Meinecke, Douglas L
Project Start
2000-04-01
Project End
2011-04-30
Budget Start
2006-05-04
Budget End
2007-04-30
Support Year
5
Fiscal Year
2006
Total Cost
$485,307
Indirect Cost
Name
University of Colorado Denver
Department
Psychiatry
Type
Schools of Medicine
DUNS #
041096314
City
Aurora
State
CO
Country
United States
Zip Code
80045
Smucny, Jason; Rojas, Donald C; Eichman, Lindsay C et al. (2013) Neural effects of auditory distraction on visual attention in schizophrenia. PLoS One 8:e60606
Tregellas, Jason R; Tanabe, Jody; Rojas, Donald C et al. (2011) Effects of an alpha 7-nicotinic agonist on default network activity in schizophrenia. Biol Psychiatry 69:7-11
Slavov, Svetoslav H; Radzvilovits, Maksim; LeFrancois, Susan et al. (2010) A computational study of the binding of 3-(arylidene) anabaseines to two major brain nicotinic acetylcholine receptors and to the acetylcholine binding protein. Eur J Med Chem 45:2433-46
Tregellas, Jason R; Olincy, Ann; Johnson, Lynn et al. (2010) Functional magnetic resonance imaging of effects of a nicotinic agonist in schizophrenia. Neuropsychopharmacology 35:938-42
Hibbs, Ryan E; Sulzenbacher, Gerlind; Shi, Jianxin et al. (2009) Structural determinants for interaction of partial agonists with acetylcholine binding protein and neuronal alpha7 nicotinic acetylcholine receptor. EMBO J 28:3040-51
Arias, H R; Xing, H; Macdougall, K et al. (2009) Interaction of benzylidene-anabaseine analogues with agonist and allosteric sites on muscle nicotinic acetylcholine receptors. Br J Pharmacol 157:320-30
Freedman, Robert; Olincy, Ann; Buchanan, Robert W et al. (2008) Initial phase 2 trial of a nicotinic agonist in schizophrenia. Am J Psychiatry 165:1040-7
Olincy, Ann; Harris, Josette G; Johnson, Lynn L et al. (2006) Proof-of-concept trial of an alpha7 nicotinic agonist in schizophrenia. Arch Gen Psychiatry 63:630-8
Talley, Todd T; Yalda, Samar; Ho, Kwok-Yiu et al. (2006) Spectroscopic analysis of benzylidene anabaseine complexes with acetylcholine binding proteins as models for ligand-nicotinic receptor interactions. Biochemistry 45:8894-902
Harris, Josette G; Kongs, Susan; Allensworth, Diana et al. (2004) Effects of nicotine on cognitive deficits in schizophrenia. Neuropsychopharmacology 29:1378-85

Showing the most recent 10 out of 12 publications